Navigation Links
CTI Issues Statement Regarding Tosedostat Clinical Trial
Date:6/24/2013

SEATTLE, June 25, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today issued the following statement regarding the notification of the U.S. Food and Drug Administration (the "FDA") partial clinical hold on tosedostat (IND 075503), the Company's aminopeptidase inhibitor under development for the treatment of blood-related cancers, that is being studied in an investigator-sponsored trial and not by CTI. CTI's primary development programs are the ongoing Phase 3 trial of pacritinib, the Company's JAK2/FLT3 inhibitor being evaluated for patients with myelofibrosis, and the post-approval commitment study of PIXUVRI® (pixantrone).

This is a partial clinical hold of only part of the clinical work requested under the investigational new drug ("IND") application. Under a partial clinical hold, although a specific protocol or part of a protocol is not allowed to proceed, other parts of such protocol or other protocols are allowed to proceed under the IND. With this partial clinical hold, the Company may not enter new patients onto any of the ongoing tosedostat protocols until agreement is reached with the FDA.

After a study has been placed on partial clinical hold, the sponsor provides additional information and discusses the adverse event with the FDA to understand whether or not it was associated with the drug or due to another cause. The Company has begun work to comply with the FDA request and expects to be able to submit these data to the FDA in the coming weeks. For additional information, please refer to the Current Report on Form 8-K filed by the Company on June 24, 2013.

Recent Tosedostat Publication
In March 2013, Lancet Oncology published results from the OPAL Phase 2 study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia (AML). The trial showed that once-daily oral tosedostat resulted in a disease contro
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lilly Issues Alert for Illegal Scams Involving Fraudulent Checks and Online Job Requests
2. Celsion Corporation Issues Statement Regarding Misleading Blog Entry
3. Zydus Pharmaceuticals USA Inc. Issues Voluntary Nationwide Recall of Warfarin 2 mg Tablets, Lot MM5767, Expiration Date June 2014, Due to Oversized Tablets
4. Endeavor Power Corporation Issues Corrections on two of its earlier Press Releases dated January 9, 2013 and March 8, 2013
5. Neiman Center Issues Policy Brief Outlining Innovative Health Care Payment Models to Provide Cost-Effective Specialty Care for Patients
6. ISPE Patient Initiative Issues Survey Regarding Patient Experience with Clinical Materials
7. Ampio Pharmaceuticals Issues Statement Regarding Misleading Blog
8. American Academy of Ophthalmology Issues Statement on Provisions to Pharmaceutical Compounding Quality and Accountability Act
9. Royalty Pharma Issues Investor Presentation Highlighting The Strategic And Financial Advantages Of Its Offer To Acquire Elan For $12.50 Per Share In Cash
10. BD Issues 2012 Sustainability Report
11. TNI BioTech, Inc. Corporations CEO Issues Letter to Shareholders Discussing Recent Events
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , Feb. 27, 2015  Two ... increasing in applications as their effectiveness is ... Kalorama Information.  Kalorama Information says that while ... the most powerful tool in proteomic biomarker ... MS) through its traditional techniques has struggled ...
(Date:2/26/2015)... , Feb. 26, 2015  Tandem Diabetes Care®, Inc. ... and manufacturer of the t:slim® and t:flex™ Insulin Pumps, ... of 5,250,000 shares of its common stock at a ... net proceeds to Tandem from this offering are expected ... commissions and other estimated offering expenses payable by Tandem. ...
(Date:2/26/2015)... VIEW, Calif. , Feb. 26, 2015  IRIDEX Corporation ... release its fourth quarter and full year 2014 financial results ...   In conjunction with the release, the Company will host ... p.m. Eastern Time on Thursday, March 5, 2015 ... business developments. Interested parties may access the live ...
Breaking Medicine Technology:Report: "Softer" Mass Spec Techniques Gaining Popularity in Biomarker Discovery 2Report: "Softer" Mass Spec Techniques Gaining Popularity in Biomarker Discovery 3Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common Stock 2Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common Stock 3IRIDEX Announces Fourth Quarter and Full Year 2014 Conference Call and Release Date 2
... URBANA, Ill., Dec. 6, 2011  Bayer HealthCare and ... outcomes-based contract for people with relapsing-remitting multiple sclerosis ... reduce the frequency of clinical exacerbations.  The agreement ... HealthCare in the U.S. and is defined by ...
... 2011 Aethlon Medical, Inc. (OTCBB:AEMD), the pioneer in ... cancer, announced today that a cancer research study to ... Aethlon Hemopurifier® to capture tumor-secreted exosomes from the blood ... approval to begin studies at the Sarcoma Oncology Center, ...
Cached Medicine Technology:Bayer HealthCare and Health Alliance Medical Plans Enter Outcomes-based Agreement 2Bayer HealthCare and Health Alliance Medical Plans Enter Outcomes-based Agreement 3Bayer HealthCare and Health Alliance Medical Plans Enter Outcomes-based Agreement 4Aethlon Medical Announces Approval and Initiation of Cancer Research Study to Target Tumor-Secreted Exosomes 2Aethlon Medical Announces Approval and Initiation of Cancer Research Study to Target Tumor-Secreted Exosomes 3
(Date:2/28/2015)... Aliso Viejo, California (PRWEB) February 28, 2015 ... announced the release of a new overlay plugin for Final ... Pixel Film Studios. , “FCPX Overlay Chromatic gives users total ... X,” said Christina Austin, CEO of Pixel Film Studios. “FCPX ... while maintaining an easy to use interface.” , FCPX Overlay ...
(Date:2/28/2015)... Viejo, California (PRWEB) February 28, 2015 ... release of TransFold Volume 2. A fully customizable ... X. , “TransFold Volume 2 gives users total control ... said Christina Austin, CEO of Pixel Film Studios. “TransFold ... Pro X editor.” , TransFold Volume 2 from Pixel ...
(Date:2/28/2015)... 28, 2015 My Shiney Hiney® LLC., the ... team to Las Vegas, Nevada for the annual ASD Market ... of the leading consumer-goods tradeshows and My Shiney Hiney will ... event. My Shiney Hiney can be found at booth number ... for the at-home personal hygiene brush and cleansing system exclusively ...
(Date:2/27/2015)... MA (PRWEB) February 27, 2015 ... mobility management services, and one of the ... announced support for Bell Mobility within their CLEAN ... of services. Wireless Analytics’ newly developed Bell ... reporting for the Canadian wireless carrier’s business customers. ...
(Date:2/27/2015)... February 27, 2015 Just a little ... for those suffering from Sjögren’s Syndrome after a new ... researchers at the University of Buffalo and Immco Diagnostics, ... research was to develop a new diagnostic test ... presence of new autoantibodies. Researchers aimed to develop a ...
Breaking Medicine News(10 mins):Health News:Pixel Film Studios released a new overlay plugin entitled FCPX Overlay Chromatic Grunge 6K exclusively for Final Cut Pro X users 2Health News:Announcing a New TransFold Transition Pack from Pixel Film Studios for Final Cut Pro X Professionals 2Health News:My Shiney Hiney® to Participate in ASD Market Week 2015 2Health News:Bell Mobility Gains Traction With Enterprises; Is Added to Wireless Analytics’ CLEAN Platform™ 2Health News:Bell Mobility Gains Traction With Enterprises; Is Added to Wireless Analytics’ CLEAN Platform™ 3Health News:Breakthrough Blood Test for Early Detection of Sjögren’s Syndrome Now Available 2
... , TARRYTOWN, N.Y., Nov. 24 ... presentation at the 21st Annual Piper Jaffray Healthcare Conference on ... 4:00 p.m. Eastern Time. The session may be accessed ... Investor Relations page. An archived version of the presentation ...
... few fear cyberbullying, survey finds , TUESDAY, Nov. 24 ... say their children use the Internet without adult supervision, ... about online predators, a new survey has found. , ... Mott Children,s Hospital National Poll on Children,s Health, show ...
... SHANGHAI, Nov. 24 /PRNewswire-Asia/ -- Sundia ... is proud to announce,that the company received the Red Herring ... top 100 private technology companies in the Asia Pacific,region. , ... 100 list every year for various,regions, such as North America, ...
... ... treatment—and suggests the need to re-examine reimbursement. , ... Alpharetta, GA (Vocus) November 24, 2009 -- The proposed ... consumers, insurers, legislators and policy makers all weighing in with their views on what ...
... ... to expand his reach and keep an ongoing dialogue with patients. Through Facebook, Twitter, and ... practice and seeks to answer any questions that patients may have. , ... Atlanta, GA (Vocus) November 24, 2009 -- A ...
... ... Sinusitis patients life is regularly impacted by acute ... Nasal nebulizer offers the convenience of treating all types of Sinusitis ... found 82.9% of patients treated with Sinus Dynamics™ nasal nebulized antibiotics ...
Cached Medicine News:Health News:Parents Worry About Their Kids' Safety on the Internet 2Health News:Sundia MediTech Receives Red Herring Asia Top 100 Award 2Health News:Jackson & Coker Industry Report Addresses Health Care Reform 2Health News:Jackson & Coker Industry Report Addresses Health Care Reform 3Health News:Atlanta Plastic Surgeon Using Social Media To Connect with Patients 2Health News:Atlanta Plastic Surgeon Using Social Media To Connect with Patients 3Health News:Sinusitis Treatment Using Nebulized Medications to Treat Sinusitis Rather than Sinus Surgery 2Health News:Sinusitis Treatment Using Nebulized Medications to Treat Sinusitis Rather than Sinus Surgery 3Health News:Sinusitis Treatment Using Nebulized Medications to Treat Sinusitis Rather than Sinus Surgery 4
Ideal for abdominal and back procedures....
Female High Waist Briefs...
Provides upper and lower arm support. Extends to the lower arm and across the shoulders. Has two columns of hook & eye closure for added adjustability....
Short-Sleeve Bolero for targeted compression in the upper arms, back and shoulder areas. Plush-shielded hook and eye front closure for comfort and convenient application....
Medicine Products: